Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

InMed Pharmaceuticals (INM) Gross Margin: 2022-2025

Historic Gross Margin for InMed Pharmaceuticals (INM) over the last 4 years, with Jun 2025 value amounting to 34.53%.

  • InMed Pharmaceuticals' Gross Margin fell 302.00% to 35.99% in Q3 2025 from the same period last year, while for Sep 2025 it was 33.69%, marking a year-over-year increase of 197.00%. This contributed to the annual value of 34.53% for FY2025, which is 1058.00% up from last year.
  • As of FY2025, InMed Pharmaceuticals' Gross Margin stood at 34.53%, which was up 44.20% from 23.94% recorded in FY2024.
  • Over the past 5 years, InMed Pharmaceuticals' Gross Margin peaked at 49.89% during FY2022, and registered a low of 23.94% during FY2024.
  • Its 3-year average for Gross Margin is 30.80%, with a median of 33.93% in 2023.
  • In the last 5 years, InMed Pharmaceuticals' Gross Margin plummeted by 1,597bps in 2023 and then surged by 1,058bps in 2025.
  • MRY analysis of 4 years shows InMed Pharmaceuticals' Gross Margin stood at 49.89% in 2022, then plummeted by 32bps to 33.93% in 2023, then fell by 29bps to 23.94% in 2024, then surged by 44bps to 34.53% in 2025.
  • Its last three reported values are 34.53% in FY2025, 23.94% for FY2024, and 33.93% during FY2023.